InvestSMART

Nova Eye Medical Limited (ASX:EYE)

ALERT: Price-sensitive ASX Announcement for EYE
Current share price for EYE : $0.110 -0.035 (-24.14%)+
Announcement
Release
29 Apr 2026 8:26AM
Price at Release
$0.145
Full Release
download
Summary
Nova Eye Medical Limited reported a strong quarter ending 31 March 2026, with sales increasing by 23% year-on-year to US$5.8 million (A$8.2 million). The company experienced growth in the USA market, achieving record monthly revenue in March and initiating sales of the iTrack™ Advance device in China. Despite adverse weather early in the quarter, sales momentum was maintained, resulting in a 24% increase in last twelve months (LTM) global sales, amounting to US$22 million (A$33.2 million). The company's EBITDA loss improved to US$75,000 (A$107,000), with expectations of a breakeven or small positive EBITDA in the second half of FY26. Operating cash outflow was recorded at A$1.2 million, attributed to advance payments and currency fluctuations. Nova Eye Medical has sufficient funding, with A$1.2 million in cash and A$2.14 million in unused debt facilities, and anticipates continued improvement in cash flow from operations.
Key Points
  • Sales for the quarter were US$5.8 million, a 23% increase.
  • LTM global sales increased by 24% to US$22 million.
  • EBITDA loss improved to US$75,000.
  • Record monthly revenue achieved in the USA in March.
  • First sales of iTrack™ Advance in China.
  • Group cash outflow from operations was A$1.2 million.
  • Guidance for FY26 updated to US$21-22 million in sales (excluding China).
  • Cash balances at the end of the period were A$1.2 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.